Get the Stockscreener App
9.50
1.96%
-0.19
After Hours:
9.50
Prothena Corp Plc stock is traded at $9.50, with a volume of 403.74K.
It is down -1.96% in the last 24 hours and up +8.08% over the past month.
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
See More
Previous Close:
$9.69
Open:
$9.65
24h Volume:
403.74K
Relative Volume:
0.76
Market Cap:
$497.36M
Revenue:
$57.94M
Net Income/Loss:
$-151.18M
P/E Ratio:
-3.3789
EPS:
-2.8116
Net Cash Flow:
$-86.56M
1W Performance:
-4.71%
1M Performance:
+8.08%
6M Performance:
+5.91%
1Y Performance:
+47.63%
1-Day Range:
$9.465
$9.84
1-Week Range:
$9.465
$10.15
52-Week Range:
$6.16
$11.80
Prothena Corp Plc Stock (PRTA) Company Profile
Name
Prothena Corp Plc
Sector
Industry
Phone
011-353-1-236-2500
Address
77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2
Compare PRTA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRTA
Prothena Corp Plc
|
9.50 | 512.54M | 57.94M | -151.18M | -86.56M | -2.8116 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Prothena Corp Plc Stock (PRTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-25 | Downgrade | BofA Securities | Neutral → Underperform |
| May-27-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-27-25 | Downgrade | Jefferies | Buy → Hold |
| May-27-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Apr-24-23 | Initiated | SVB Securities | Outperform |
| Jan-27-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-28-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Jun-18-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-08-21 | Reiterated | Oppenheimer | Outperform |
| May-26-21 | Initiated | Citigroup | Buy |
| Feb-26-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-12-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-02-21 | Upgrade | BTIG Research | Neutral → Buy |
| Dec-07-20 | Initiated | H.C. Wainwright | Buy |
| Jul-09-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-19-19 | Upgrade | Evercore ISI | In-line → Outperform |
| May-21-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-23-18 | Downgrade | Jefferies | Buy → Hold |
| Apr-05-18 | Reiterated | Barclays | Overweight |
| Nov-20-17 | Downgrade | Wedbush | Outperform → Neutral |
| Sep-29-17 | Reiterated | BTIG Research | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Jefferies | Buy |
| Apr-12-17 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-17 | Initiated | Piper Jaffray | Overweight |
| Mar-02-17 | Initiated | Instinet | Buy |
| Dec-21-16 | Initiated | SunTrust | Buy |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Aug-04-16 | Reiterated | Barclays | Overweight |
| May-13-16 | Initiated | Barclays | Overweight |
| Feb-19-16 | Reiterated | Wedbush | Outperform |
| Jan-21-16 | Initiated | Credit Suisse | Outperform |
View All
Prothena Corp Plc Stock (PRTA) Latest News
PRTAProthena Corp Plc Options - Finviz
Price to sales forward of Prothena Corp. Plc – MUN:0PT - TradingView
Enterprise value to revenue forward of Prothena Corporation plc – NASDAQ:PRTA - TradingView
Enterprise value to EBIT forward of Prothena Corporation plc – NASDAQ:PRTA - TradingView
Price to book forward of Prothena Corp. Plc – MUN:0PT - TradingView
Enterprise value to EBITDA forward of Prothena Corp. Plc – MUN:0PT - TradingView
Enterprise value to revenue forward of Prothena Corp. Plc – MUN:0PT - TradingView
Prothena Corp, Parkinson antibody program draws attention for the stock - AD HOC NEWS
Prothena Corp. Plc Actuals & Estimates (NASDAQ:PRTA) - TradingView
Prothena Corp. Plc Actuals & Estimates (DUS:0PT) - TradingView
Prothena Corp. Plc Actuals & Estimates (SWB:0PT) - TradingView
PRTA Forecast — Price Target — Prediction for 2027 - TradingView
0PT Forecast — Price Target — Prediction for 2027 - TradingView
Prothena Corporation PLC (PRTA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Prothena Corporation Plc (NASDAQ:PRTA) About To Shift From Loss To Profit - Moomoo
Prothena Corp plc strategy in focus, shares watched against biotech peers - AD HOC NEWS
Prothena Corporation PLC (PRTA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Prothena Corporation PLC (PRTA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Prothena Corporation PLC (PRTA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Prothena Corporation PLC (PRTA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Price-Driven Insight from (PRTA) for Rule-Based Strategy - Stock Traders Daily
(PRTA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
PRTA Q1 2026 Earnings: Surprise EPS Beat Driven by Milestone Revenue, Stock Edges HigherDownward Estimate Revision - The Legal Advocate
(PRTA) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Penbrook Management LLC's Prothena Corp PLC(PRTA) Holding History - GuruFocus
Prothena (NASDAQ: PRTA) investors approve board, KPMG and executive pay - Stock Titan
Rubric Capital and David Rosen disclose 9.29% stake in Prothena (PRTA) - Stock Titan
Prothena Corp plc stock (IE00B91XRN20): Biotech investor focus amid pipeline updates - AD HOC NEWS
Number of shareholders of Prothena Corp. Plc – DUS:0PT - TradingView
PRTA Stock Price, Quote & Chart | PROTHENA CORP PLC (NASDAQ:PRTA) - ChartMill
William Scully reports 10.27% stake in PROTHENA (NASDAQ: PRTA) - Stock Titan
Prothena Corp. Down Over 9%, on Pace for Largest Percent Decrease Since May 2025 -- Data Talk - Moomoo
Earnings Beat: Prothena Corporation plc Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - Yahoo Finance
Prothena (PRTA) Heavy US$244 Million Annual Loss Tests Bullish Profitability Narratives - Sahm
Prothena Posts Q1 Earnings as Revenues Surge on Milestone Payment - Yahoo Finance
Prothena (PRTA) Highlights Progress in Parkinson's Research and Collaborations - GuruFocus
Citizens raises Prothena stock price target on milestone payment By Investing.com - Investing.com UK
Prothena (PRTA) Revises 2026 Cash Outlook and Operating Expenses - GuruFocus
Prothena (NASDAQ:PRTA) Smashes Q1 Estimates on $50 Million Milestone Payment, Shares Steady - ChartMill
Prothena: Q1 Earnings Snapshot - marketscreener.com
Milestone revenue lifts Prothena (NASDAQ: PRTA) cash and pipeline - Stock Titan
Prothena (NASDAQ: PRTA) posts $32.7M Q1 profit and lifts 2026 cash outlook - Stock Titan
A $50M Novo milestone reshaped Prothena’s 2026 cash outlook - Stock Titan
Tranche Update on Prothena Corporation plc's Equity Buyback Plan announced on February 27, 2026. - marketscreener.com
Prothena to Report First Quarter 2026 Financial Results on May 7 - ChartMill
3 Growth Companies Insiders Are Eager To Hold - Sahm
Prothena (NASDAQ:PRTA) Shares Up 5.9%Time to Buy? - MarketBeat
FDA Fast Track granted to Phase 3 drug for ATTR-CM - Stock Titan
Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy - The Joplin Globe
Prothena authorizes up to $100 million share repurchase plan - MSN
PRTA SEC FilingsProthena 10-K, 10-Q, 8-K Forms - Stock Titan
Prothena Corp Plc Stock (PRTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Prothena Corp Plc Stock (PRTA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SCULLY WILLIAM P | 10% Owner |
Jun 11 '26 |
Buy |
8.17 |
125,000 |
1,021,225 |
1,061,000 |
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):